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Magnetoliposomes: opportunities and challenges
Abstract: Combining liposomes with magnetic nanoparti-
cles is an intriguing approach to create multifunctional ves-
icles for medical applications, which range from controlled 
drug delivery vehicles to diagnostic imaging enhancers. 
Over the past decade, significant effort has been invested 
in developing such hybrids – widely known as magnetoli-
posomes – and has led to numerous new concepts. This 
review provides an overview on of the current state of the 
art in this field. The concept of magnetic fluid hyperther-
mia and stimuli-responsive nanoparticles for drug delivery 
is briefly recapitulated. The materials needed  for these 
hybrids are addressed as well. The three typically followed 
approaches to associate magnetic nanoparticles to the 
liposomes are described and discussed more in detail. The 
final chapters are dedicated to the analytical methods used 
to characterize these hybrids and to theoretical considera-
tions relevant for bilayer-embedded nanoparticles.
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Introduction
A nanoparticle (NP) is defined as a material with all 
three external dimensions in the nanoscale (ISO/TS: 
27687:2008), i.e., below 100 nm. The current choice of 
available NPs is colossal and ranges from relatively simple 
single NPs to highly complex surface derivatized NPs or 
NP assemblies. All engineered NPs have one common link: 
Their chemical, physical and biological properties can 
differ considerably from the bulk material properties. For 
example, iron oxides – such as maghemite (γ-Fe2O3) and 
magnetite (Fe3O4) – lose their permanent magnetization 
below a certain size, which is typically below 20 nm (1). 
At this point, iron oxide NPs possess only one magnetic 
domain, and consequently exhibit superparamagnetic 
behavior at temperatures above the so-called blocking 
temperature (2). Nowadays, magnetic NPs are found in 
a rapidly increasing number of applications, including 
catalysis (3), sensing (4), and filtration (5). In nanomedi-
cine, superparamagnetic iron oxide NPs (SPIONs) have 
gained wide acceptance in diagnosis and are used for 
contrast enhancement in magnetic resonance imaging 
(MRI) (6), (stem) cell tracking and labeling (7) or magnetic 
separation technologies (e.g., rapid DNA sequencing) and 
ultrasensitive diagnostic assays (8).
The benefits of magnetic NPs for therapeutic purposes 
are indisputable, and magnetic targeting for drug or gene 
delivery and magnetic fluid hyperthermia (MFH) are argu-
ably the two most important potential therapeutic applica-
tions. In particular, SPIONs are promising because of their 
outstanding magnetic behavior (9), their biocompatibility 
(10), and the large amount of information available on 
these materials. However, the process of converting basic 
research into clinical nanomedicine settings and commer-
cially sustainable products is long and complicated (11), 
and the acceptance and integration of nanotechnologies 
particularly into nanomedicine are very challenging.
Magnetic fluid hyperthermia – 
a brief recapitulation
Magnetic fluid hyperthermia (MFH) was first proposed by 
Gilchrist and colleagues (12). In short, it involves the injec-
tion of SPIONs directly into a specific tissue or organ (e.g., 
lymph nodes) and the subsequent exposure to an alternat-
ing magnetic field (AMF) to heat the region in question up 
to 45 to 47°C. Temperatures so far above the physio logical 
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norm can lead to widespread necrosis, coagulation or – 
depending on the temperature – even carbonization (13). 
This technique is mostly used as a complementary therapy 
to radiation or chemotherapy with the motivation to render 
cells of a tumor more sensitive to the principal treatment 
(14). The method is fundamentally linked to the nanosize of 
the magnetic particles, which – when exposed to an AMF 
– dissipate heat through relaxation losses. Typically, the 
heating potential of magnetic NPs depends on the material 
itself, its concentration and size (distribution) (15). Energy 
dissipation occurs either through the physical rotation of 
the NP in the fluid (Brownian relaxation) or by the rotation 
of the atomic magnetic moments within the particle itself 
(Néel relaxation) (16). According to the theoretical model for 
the volumetric energy dissipation rate developed by Rosens-
weig (9), the energy dissipation rate (i.e., heating potential) 
increases with the applied AMF (i.e., its amplitude and fre-
quency). However, it has been shown that a strong AMF can 
lead to non-specific heating due to eddy currents.
In recent years, significant effort was dedicated to 
optimize the magnetic materials (15). This development 
is, however, related to the applied magnetic field, and 
many reports (17, 18) have investigated the effects of AMF 
on healthy tissues in order to elucidate the maximum 
magnetic field strength at a given frequency applicable 
to humans (15). Currently, magnetic field conditions are 
chosen to be compliant with what has been approved in 
Europe for MFH. For example, for treatment of glioblas-
toma multiforme (MagForce, Berlin, Germany) magnetic 
field frequencies in the order of 100–200 kHz at around 
20 mT are typically chosen. In addition to the parameters 
related to the magnetic field, i.e., alternating field ampli-
tude and frequency, the surrounding medium, type of 
magnetic material, and particle crystallinity play a crucial 
role. As demonstrated theoretically and experimentally 
by Hergt and colleagues (19), adequate mean particle size 
and narrow particle size distribution are extremely impor-
tant requirements for efficient heating. Moreover, in order 
to successfully annihilate cancer cells, it is imperative 
that sufficient heat is locally administered to account for 
the losses to the surrounding tissue. This point has been 
addressed by theoreticians and experimentalists with 
controversial results (20, 21).
Nanomaterials for drug delivery
The ability to directly deliver drugs to relevant cell types, 
and possibly to specific intracellular organelles, is essen-
tial (22) for optimally exploiting the potential of any drug 
delivery vehicle. To achieve this, many nanomaterials have 
been highlighted as favorable modalities, and the majority 
of the currently available formulations comprise “soft” NPs 
(e.g., organic polymers and liposomes) (23). Liposomes are 
artificial vesicles consisting of a phospholipid bilayer and 
have been promoted for many years as future drug delivery 
vehicles. The contributions of numerous researchers over 
five decades have led to significant advances in the field, 
and liposomes are perhaps the first nanocarriers which 
have succeeded in translating from bench to bedside (24), 
Doxil/Caelix being the most prominent example.
Historically, classical or first-generation drug deliv-
ery nanocarriers comprise a container, (e.g., a liposome) 
and an active principle (i.e., the drug molecule). Second-
generation nanocarriers were developed to target their 
therapeutic site via antibodies and other biomolecules. 
Third-generation nanocarriers are designed to fulfill more 
complex functions, such as time-controlled deployment 
of active vesicles across different biological barriers and 
different subcellular targets.
In analogy to liposome development, inorganic NPs are 
nowadays promoted as potential drug delivery vehicles, but 
despite important progress, many of the presently investi-
gated delivery systems are far from meeting the required 
needs. Further careful design is thus imperative (25). In this 
category, biocompatible SPIONs (10) are conceived as ben-
eficial, alternative targeting tools compared to other NPs, 
as they are easily synthesized and surface-functionalized 
(26). Due to their advantageous magnetic properties (9), 
SPIONs can be used for magnetic targeting, which relies 
on the delivery of magnetic NPs to the desired target area 
through the application of a magnetic field gradient (27). 
Following successful targeting, the SPIONs remain within 
the desired region for optimal therapeutic treatment. Then 
they are subsequently released and excreted. Recently, such 
a concept was aptly portrayed by Kumar and colleagues 
(28), who demonstrated that magnetic NPs – injected in the 
tail of mice – were successfully directed to the heart and 
kidneys via an external magnetic field.
Stimuli-responsive nanoparticles
Stimuli-responsive NPs are becoming more and more 
prominent in the medical sciences and increasingly 
encouraging in the development of next-generation 
disease therapies (29, 30). To name some auspicious 
examples, applications may include diagnostic imaging, 
targeted drug release, hyperthermia treatment or a com-
bination of them. In general, multifunctional materials, 
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which aim at providing both treatment options and diag-
nostic potential are particularly sought after to comple-
ment the emerging field of theranostics.
In regard to targeted drug delivery, stimuli-responsive 
NPs are visionary concepts to deliver and release a drug 
exactly where it is needed. However, the release needs to 
be modulated, as passive diffusion out of the carrier alone 
is usually slow. Drug release by an external stimulus 
(e.g., a magnetic field, infrared light, pH etc.) is an ideal 
approach, as it enables a spatial and temporal control 
over the drug release. As triggers, SPIONs are again ideal 
candidates due to their size- and material-dependent 
physicochemical properties, which in turn bestow them 
with superlative conditions to confer any nanocarrier the 
ability to fulfill additional tasks.
One of the most intriguing stimuli-responsive NP-
based drug carriers is arguably the magnetoliposome, i.e., 
a combination of a liposomal drug carrier and magnetic 
NPs. First described by De Cuyper and Joniau in 1988 (31), 
magnetoliposomes have become remarkable hybrids due 
to the multivalent properties of both the carriers and the 
triggers. Liposomes may be designed to be thermosensi-
tive, i.e., to undergo a phase transition from an imperme-
able gel state to a permeable liquid-crystalline state when 
a defined temperature barrier is reached (32). As men-
tioned before, magnetic NPs exhibit remarkable heating 
effects when exposed to an AMF (9). In regard to magne-
toliposomes, this inherent property is pivotal: If generated 
close to the main release barrier (i.e., the phospholipid 
membrane), the resulting thermal energy may be used to 
alter the membrane and render it permeable to an encap-
sulated drug.
Combining these two independent systems yields a 
versatile nanoplatform, which may provide combined drug 
delivery and hyperthermia treatment at a specific target 
site under co-instantaneous tracking via MRI (Figure 1).
In short, this covers practically the entire scope 
of application, which is desirable for third-generation 
nanocarriers. Although still far away from direct clinical 
application, there has been significant progress in the 
development and understanding over the past decade, 
ranging from general biophysical investigations to trig-
gered release demonstrations. Nevertheless, a basic 
understanding of all materials involved still remains the 
prerequisite stage to fulfill before moving to the next step.
This review aims at presenting the most recent devel-
opments in the field, the most common materials used 
and the hybrids in general. Moreover, recent biophysical 
findings by the authors will be commented on to provide 
a general overview on what is possible, what has been 
done and – last but not least – what is still possible in the 
future.
Figure 1 Schematic representation of a SPION-liposome hybrid drug delivery system specifically designed for the triggered release of an 
encapsulated hydrophilic drug.
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Figure 2 Transmission electron micrographs of SPIONs obtained by co-precipitation (A) or by thermal decomposition (B). Figure 2C illus-
trates possible SPION surface functionalizations to render them hydrophilic, using e.g. carboxylates (I) or tetramethyl-ammonium hydroxide 
(II) or hydrophobic using fatty acids (III) or dopamine derivatives (IV).
SPION-liposome hybrids – 
obtaining the materials
The centerpiece of the magnetoliposome is unmistak-
ably the type of NP used. SPIONs are the most evident 
candidate. To obtain them, there are numerous estab-
lished wet-chemical methods including microemulsions 
or hydrothermal syntheses (2) in addition to gas phase 
methods such as thermal decomposition in hot-wall 
reactors or flame synthesis (33). While the wet-chemical 
bottom up approaches typically better control particle 
characteristics such as size or shape, flame syntheses 
allow for continuous and therefore large-scale produc-
tion of magnetic NPs. The most dominant and widely used 
technique in the biomedical field is the co-precipitation 
method of aqueous Fe2+/Fe3+ salt solutions by the addi-
tion of a base under inert atmosphere (34). This approach 
yields magnetite NPs, which are easily oxidized to magh-
emite (Figure 2A). Adjusting particle size and size distri-
bution is extremely challenging with this process, and 
the control of pH, ionic strength and seed concentration 
is crucial. Since the blocking temperature depends on the 
size (distribution) of the NPs, large polydispersity (i.e., a 
broad particle size distribution) results in a wide range 
of blocking temperatures and consequently suboptimal 
magnetic behavior for many applications (34). Nonethe-
less, this method is arguably the most popular source of 
SPIONs for magnetoliposomes, as large quantities can be 
synthesized at once.
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To obtain much more monodisperse SPIONs, synthe-
sis by thermal decomposition (35) has become the leading 
approach. In short, an organometallic precursor (e.g., iron 
oleate (36), iron acetylacetonate, iron carbonyls) is ther-
mally decomposed in a high boiling point solvent (e.g., 
octyl ether, hexadecene, eicosane). This approach yields 
highly crystalline NPs with narrow size distributions 
(Figure 2B) (35). Furthermore, the size can be tuned by the 
choice of solvent, the reaction time and the reactant ratios. 
The produced SPIONS are stabilized by a surface-attached 
oleate molecule and dispersed in an organic solvent. Con-
sequently, additional steps might be required to transfer 
the SPIONs to an aqueous environment. This phase trans-
fer relies on NP surface derivatization strategies replac-
ing the originally grafted hydrophobic molecule with 
hydrophilic compounds, or direct functionalization of the 
surface-grafted hydrophobic molecules themselves (37). 
Surface chemistry not only determines the colloidal stabil-
ity of the NPs, but also their association to the liposome, 
i.e., whether they will be embedded in the hydrophobic 
bilayer or within the hydrophilic lumen. An arsenal of 
molecules and surface chemistry strategies are available, 
and several candidates were used to date. A selection is 
highlighted in Figure 2C.
For NPs encapsulated in the lumen or grafted to the 
surface, citrate (38, 39) and oleate (overcoated by a hydro-
philic ligand, (40) e.g., a second lipid layer) stabilized 
SPIONs are the most frequently used candidates. For NPs 
embedded in the lipid bilayer, SPIONs coated with oleic 
acid (41–43) are the favored choice. Another alternative 
was presented by Amstad and colleagues (44) by introduc-
ing SPIONs stabilized with palmityl-nitroDOPA (Figure 2C, 
IV) into the lipid membrane, arguing that such particles 
were less prone to aggregation than standard oleic acid-
coated SPIONs and that they embed themselves more will-
ingly in between the bilayer.
In all, choosing the synthetic approach and surface 
coating of the NP is the first step to develop SPION-lipo-
some hybrids, and should not be taken lightly. Other 
factors such as overall NP geometry are of equal impor-
tance and might contribute in yielding more basic infor-
mation on lipid-nanoparticle interactions in general.
On the other hand, the choice of lipids determines 
the phase transition temperature, which is typically set 
only a few degrees above body temperature (e.g., around 
42°C). Changing the composition of the liposome bilayer, 
e.g., by including cholesterol, is known to reduce the 
leakage of drug molecules from the liposomes by “tight-
ening” the bilayer (45). As a long blood circulation time is 
generally desirable for any vesicle intended for medical 
usage, adding a small percentage of Polyethylene glycol 
(PEG)-derivatized lipids in the membrane is an option 
to obtain this property. PEG chains reduce the overall 
uptake efficiency by macrophages, and liposomes with 
this attribute are termed “stealth” (45). In all, the avail-
able selection – counting both natural and synthetic 
phospholipids – is immense and way beyond the scope 
of this review.
Magnetoliposomes and the state of 
the art
The NP surface properties determine where the particles 
will spatially be located within the liposome. Over the past 
years, numerous variations of magnetoliposomes have 
been presented, and a selection is highlighted in Table 1. 
Principally, research is concentrated on controlling the 
release of an encapsulated drug. However, their utility as 
MRI contrast agents has been presented on several occa-
sions (39, 52, 55). Other applications, such as cell sorting 
and gene delivery, have also been addressed (64).
Three different approaches are possible to associate 
the SPIONs to the liposomes (Figure 3). The two strate-
gies which are increasingly becoming seminal are either 
to encapsulate the magnetic NPs directly within the lipo-
some lumen (38, 48, 49), the other to embed them in 
between the lipid bilayer (41, 43, 44). Although pursued 
with other inorganic NPs [e.g., gold (65)], directly conju-
gating SPIONs to the liposome surface has only margin-
ally been done (42).
Depending on the final application, the spatial location 
of the SPIONs within the hybrid is a determining factor: for 
MRI tracking, NPs encapsulated in the lumen are preferred. 
However, when using such hybrids as drug carriers, embed-
ding the SPIONs directly in between the lipid bilayer seems 
more beneficial, as SPIONs in the liposome lumen might 
impair or affect any co-encapsulated drug even before 
the membrane actually becomes permeable. Moreover, 
the energy, which is required to permeate the membrane, 
should be delivered directly where it is needed.
Characterizing the vesicles – 
options and caveats
Visualizing and characterizing magnetoliposomes is argu-
ably the most important step in developing such hybrids 
and is indispensable in detecting the exact NP locations 
or whether the condition applies to all specimens in the 
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solution. Structural and architectural details, such as the 
SPION distribution or arrangement within the hybrids, are 
also relevant in studying the interactions of NPs and mem-
branes in general. However, the challenge lies in providing 
convincing data, which is both qualitative and quantitative, 
while assuring that the hybrids are in their native state.
For giant magnetoliposomes, light and fluores-
cence microscopy offer the most straightforward options 
to directly observe and characterized the hybrids (38). 
Nappini and colleagues (66, 67) highlighted the utility 
of these methodologies by presenting giant unilamellar 
vesicles visualized by confocal laser scanning micros-
copy, in which both vesicles and NPs were fluorescently 
labeled. With this approach, NP presence and distribu-
tion as well as dye release was elegantly shown. Another 
useful approach was presented by Beaune and colleagues 
(38): The elastic properties of the magnetoliposomes were 
investigated by studying the deformation of the vesicles 
under the effect of an applied magnetic field.
When working with much smaller hybrids, the physi-
cal constraints of light come into play, and alternative 
methods are needed. There are several techniques avail-
able ranging beyond microscopy for investigating at the 
nanoscale and particularly small vesicles (i.e.,  < 200 nm). 
As an example, scattering techniques – such as dynamic 
light scattering (DLS) or small angle X-ray and neutron 
scattering (SAXS and SANS) – can be used to elaborate the 
size of the vesicles, which in turn provides critical infor-
mation on sample homogeneity. As an example, Amstad 
and colleagues (44) have successfully employed SANS to 
characterize both the sample homogeneity and the change 
in membrane thickness when loaded with SPIONs. None-
theless, complementary visualization by microscopy to 
investigate morphology or appearance of the sample is 
unavoidable.
Transmission electron microscopy (TEM) is still the 
method of choice and has been widely used in this context 
(42, 46). However, conventional TEM techniques require 
a high vacuum environment, which is – particularly in 
the case of liposomes – highly destructive for any water-
rich sample. Although samples can be preserved, e.g., by 
chemical fixation, there are still countless artifacts which 
are created by either the fixation procedure itself and/
or sample drying. Moreover, this step inevitably leads to 
a randomized location of the unassociated NPs over the 
TEM grid. Consequently, correct and objective interpreta-
tion and discrimination between liposome associated and 
non-associated NPs is very challenging (Figure 4).
Although straightforward, this method is not ideal to 
reliably characterize such specimens. On the other hand, 
samples can be visualized in their native state by cryo 
TEM. Unlike conventional TEM, the vesicles are preserved 
in a layer of vitreous ice, keeping them safe from drying 
effects or the vacuum during visualization. Cryo TEM has 
been used to characterize liposomes for quite some time 
and has been applied on several occasions in the context 
of NP-liposome hybrids (41, 44). Unfortunately, the reso-
lution was often not high enough to distinctly resolve 
the bilayer, a task rendered even more challenging by 
the variety of optical effects which may occur (68). Chen 
and colleagues (41) proved the presence of NPs by subse-
quent energy-dispersive X-ray spectroscopy (EDX) Electron 
microscopy in general needs to be interpreted extremely 
carefully: Merely a two-dimensional projection of the 
sample is provided by this methodology and leaves the 
three-dimensional aspects – such as the spatial location of 
the NPs in regard to the lipid bilayer – subject to specula-
tion. Deducing architectural features by relying solely on 
single projections is therefore not feasible. This query can 
be countered by cryo-electron tomography, which finally 
Figure 3 SPION-liposome hybrids. SPIONs acting as triggers to release a cargo (e.g., drug molecules) can be located in the lipid bilayer, 
the lumen, or can be grafted to the surface of the liposome (from left to right).
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Figure 4 Cryo TEM images of SPIONs and liposomes at tilt angles of –30° (A, C) and +30° (B, D). A: Although particles at –30° seem to be 
associated with the liposome membrane, the tilt image at 30° (B) challenges this interpretation: it is the loss of the third dimension during 
the projection which leads to this misinterpretation. (C) Again, a cluster of particles seemingly interacts with the liposome membrane in 
the –30° tilt angle image. This interpretation is maintained, independent of the tilt angle (D). © 2013 IEEE. Reprinted, with permission, from 
IEEE Transactions on Magnetics, Vol. 49, No. 1, January 2013.
yields information on the structural and architectural 
aspects of the vesicles. Briefly, images of the sample are 
successively taken at various stage tilt angles. The collected 
data may then be used to reconstruct and render the three-
dimensional appearance of the sample. Such data has 
been recently presented by the authors, with resolutions 
high enough to visualize the bilayer splitting around the 
inclusive SPIONs, along with three-dimensional render-
ings highlighting the NP locations and arrangements (43). 
Nonetheless, the investigation of small sample volumes is 
not sufficient for statistical relevance, which presents – in 
addition to the complexity of these techniques-the main 
limitations of cryo TEM and cryo-electron tomography.
Given the fact of the pros and cons of the aforemen-
tioned methodologies, a well-balanced combination of 
various techniques – i.e., scattering and spatial visuali-
zation by microscopy – is necessary to provide the infor-
mation needed on both a statistical and qualitative level. 
In turn, these assessments are vital for any subsequent 
upscaling and industrial perspective.
Membrane energetics – inclusion 
limits between the bilayer
The incorporation of NPs into the lipid bilayer, and in par-
ticular the question of the maximum size of the NPs that 
can be embedded, has puzzled scientists for quite some 
time. No fully rigorous model is available in the litera-
ture to effectively quantify the energy needed to deform 
a lipid bilayer and accommodate a NP. In turn, biophysi-
cal aspects and properties of lipid bilayers also come into 
play.
To date, only a simplified approach has been proposed 
by Wi and colleagues (69). Although the variational prob-
lem-based on the Helfrich model (70) used to determine 
how the lipid membrane needs to deform to accommo-
date a NP and minimize the deformation energy – was not 
solved (71), they instead made some clever assumptions on 
the geometrical configurations of the membrane. This step 
drastically reduces the complexity of the problem. Their 
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Figure 5 The energetics behind cluster-sized inclusions in between a phospholipid membrane. (A) The inclusion energy of an inclusion 
with a double spherical cap geometry, as a function of the spherical cap radius for both 100 and 1000 nanoparticles. Both radius and 
energy are normalized by the corresponding values for a spherical inclusion. (B) Energy of an inclusion with an asymmetric spherical cap 
geometry, with one radius equal to the liposome radius (taken equal to 50 nm) as a function of the number of nanoparticles in the inclu-
sion. The energy of a corresponding spherical inclusion is additionally shown for comparison (blue), along with that of a spherical cluster 
covered by a lipid monolayer (black dashed line). (C) Radii of the asymmetric spherical cap inclusion as a function of the number of particles 
in the inclusion, as compared to the spherical inclusion radius. (D) Shape of a typical asymmetric inclusion with minimal energy. (E) Cryo 
TEM images showing the membrane deformation with increasing number of embedded SPIONs, scale bar = 50 nm. Reprinted with permis-
sion from ACS Nano, Vol. 8, No. 4, 2014, Pages 3451–3460. Copyright 2014 American Chemical Society.
work has important consequences, as it allowed them 
to conclude that only spherical inclusions with a radius 
smaller than 3.5–4 nanometers can be incorporated into 
a lipid membrane. Larger spherical NPs are preferentially 
expelled by the lipid membrane and stabilized by a lipid 
monolayer. While these findings confirm some experimen-
tal observations made with quantum dots and SPIONs, they 
cannot explain the results recently obtained by the authors 
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of this review (43). In fact, inclusions with a diamond-like 
shape made of hundreds of SPIONs could be incorporated 
into the lipid membrane (Figure 5E). In order to explain 
these findings, the aforementioned theory was extended to 
inclusions with a non-spherical shape. In order to keep the 
simplicity of the original model, the model was restricted 
to spherical caps. This modified theory adds an addi-
tional degree of freedom, i.e., the radius of the spherical 
cap. For a given inclusion volume, the calculations show 
that an increase in the spherical cap radius – compared 
to a spherical inclusion – leads to a lower deformation by 
decreasing the bending energy of the membrane. However, 
a minimum is reached for a sufficiently large cap radius, 
as any further increase is penalized by the inclusion area 
becoming too large. These results, shown in Figure 5, 
demonstrate that NP clusters which can be organized into 
non-spherical assemblies are viable options to incorporate 
large quantities of SPIONs into a liposome membrane.
The importance of these results for hyperthermia 
applications is significant. In fact, the dependence of 
the heating rate of SPIONs exposed to an AMF is strongly 
dependent on the particle size, and seems to have an 
optimum for NPs with a diameter of about 20 nm (9). This 
approach offers the possibility to incorporate sufficiently 
large NPs to obtain optimal heating rate.
On the other hand, this also leads to new and currently 
unresolved problems. For example, one open question is 
whether a larger cluster of NPs remains superparamag-
netic. Losing superparamagnetism is detrimental for the 
colloidal stability of the liposomes, as it would cause them 
to exhibit dipolar interactions. Furthermore, the heating 
power generated by NP clusters has not been systemati-
cally investigated to date. While there are studies showing 
the beneficial effect of clustering on the usage of SPIONs in 
MRI (72), the impact on the heating rate is a virtually unex-
plored area. However, this query is only a single example: 
A long list of questions needs to be addressed in the future, 
starting by which composition, particles size, size distribu-
tion is required to optimize hyperthermia performance of 
the magnetoliposomes. Finding answers to these intriguing 
questions will require a fundamental change in magne-
toliposome design, and further combining the previously 
mentioned experimental characterization to modeling tech-
niques might be highly beneficial for future developments.
Conclusions and perspectives
Today, liposomes are clinically established, yet there 
is still potential to improve them. Although significant 
effort has been invested in the development of magne-
toliposomes, we still are only scratching on the tip of the 
iceberg – especially on a materials level – and the trans-
lation into the clinics is still being awaited. The efficacy 
of smart drug delivery systems, however, implies that the 
hybrids are thoroughly characterized by emerging and 
complementary techniques, which is – in our opinion – 
arguably one of the principal drawbacks in developing 
them. The complexity of these systems is highlighted by 
the multidisciplinary expertise needed, which includes 
organic and inorganic chemistry, bio- and magnetophys-
ics, pharmacology and biology. Nonetheless, the last 
decade has yielded interesting new concepts. Some of 
them have been tested in laboratory settings, and further 
advancement will hopefully bring these hybrids a step 
closer to direct clinical application in the future.
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